RT Book, Section
A1 Ursem, Carling
A1 McQuaid, Kenneth R.
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1193162414
T1 Malignancies of the Small Intestine
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193162414
RD 2024/04/25
AB Key  Clinical  Updates  in  Malignancies  of  the  Small  IntestineFor  advanced/unresectable  disease,  first-line  doublet  chemotherapy  is  standard.  Two  trials  suggest  value  from  adding  bevacizumab  to  chemotherapy.  Pembrolizumab  is  an  accepted  treatment  modality  for  mismatch  repair-deficient  tumors.National  Comprehensive  Cancer  Network.  https://www.nccn.org/professionals/physician_gls/pdf/small_bowel.pdf